
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2024

Commission File Number: 001-41598

YS BIOPHARMA CO., LTD.
(Exact name of registrant as specified in its charter)

Building No. 2, 38 Yongda Road
Daxing Biomedical Industry Park
Daxing District, Beijing, PRC
Tel: 010-89202086
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F

Director Removal

YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, announced the removal of Mr. Yi Zhang from the Board of Directors (the “Board”), effective at approximately 11:30 p.m. Eastern Time, February 12, 2024. The removal was made pursuant to Article 110(d) of the amended and restated articles of association of the Company by notice in writing addressed to Mr. Zhang at his last known address and signed by all of the directors of the Company other than Mr. Zhang, being not less than two in number.

This Current Report on Form 6-K is hereby incorporated by reference into the registration statements of the Company on [Form F-1](#) (File No. 333-271221) and [Form S-8](#) (File No. 333-273165), to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

YS Biopharma Co., Ltd.

Date: February 14, 2024

By: /s/ Hui Shao

Name: Hui Shao

Title: Director and Chief Executive Officer